Search Results | Cancer Research | American Association for Cancer Research

1-20 of 42

2 3

Sort by

Sort Order Select

Journal Articles

Abstract 3318: PSMA-targeted thorium-227 conjugate (PSMA-TTC) inhibits tumor growth and abnormal bone changes in the intratibial LNCaP xenograft model of bone-metastatic prostate cancer

Christoph Schatz, Mari I. Suominen, Matias Knuuttila, Sabine Zitzmann-Kolbe, Jukka Rissanen, Sanna-Maria Käkönen, Urs Hagemann, Arne Scholz

Cancer Res (2022) 82 (12_Supplement): 3318.

DOI: https://doi.org/10.1158/1538-7445.AM2022-3318

Published: 15 June 2022

View article

Journal Articles

Abstract 1392: Synergistic antitumor efficacy of radium-223 in combination with enzalutamide in the intratibial LNCaP prostate cancer xenograft model

Mari I. Suominen, Matias Knuuttila, Jukka Vääräniemi, Birgitta Sjöholm, Esa Alhoniemi, Dominik Mumberg, Sanna-Maria Käkönen, Arne Scholz

Cancer Res (2021) 81 (13_Supplement): 1392.

DOI: https://doi.org/10.1158/1538-7445.AM2021-1392

Published: 01 July 2021

View article

Journal Articles

Abstract 1806: Novel preclinical orthotopic and bone metastasis TNBC models for assessment of immunotherapy and chemotherapy responses

Justyna Zdrojewska, Ivan Gladwyn-Ng, Jenni H. Mäki-Jouppila, Katja M. Fagerlund, Mari I. Suominen, Ross Horn, Jukka Rissanen

Cancer Res (2021) 81 (13_Supplement): 1806.

DOI: https://doi.org/10.1158/1538-7445.AM2021-1806

Published: 01 July 2021

View article

Journal Articles

Abstract 6286: The effects of prednisone, abiraterone acetate and radium-223 dichloride on bone in the intratibial LNCaP prostate cancer model

Mari I. Suominen, Matias Knuuttila, Birgitta Sjöholm, Esa Alhoniemi, Dominik Mumberg, Jussi M. Halleen, Sanna-Maria Käkönen, Arne Scholz

Cancer Res (2020) 80 (16_Supplement): 6286.

DOI: https://doi.org/10.1158/1538-7445.AM2020-6286

Published: 15 August 2020

View article

Journal Articles

Abstract 5026: Efficacy of anti-PD-1, IDO inhibitor, chemotherapy and bone-targeting agent on tumor growth in a syngeneic bone metastasis model of triple-negative breast cancer

Tiina Emilia Kähkönen, Mari I. Suominen, Jenni H. Mäki-Jouppila, Jussi M. Halleen, Jenni Bernoulli

Cancer Res (2020) 80 (16_Supplement): 5026.

DOI: https://doi.org/10.1158/1538-7445.AM2020-5026

Published: 15 August 2020

View article

Journal Articles

Abstract 2007: Validation of a preclinical model for bone metastatic triple negative breast cancer

Justyna Zdrojewska, Mari I. Suominen, Katja M. Fagerlund, Jussi M. Halleen, Jenni Bernoulli, Johann Zimmermann

Cancer Res (2019) 79 (13_Supplement): 2007.

DOI: https://doi.org/10.1158/1538-7445.AM2019-2007

Published: 01 July 2019

View article

Journal Articles

Abstract 4588: Characterization of anti-CTLA-4 effects on tumor growth and immune microenvironment in a syngeneic CT26.WT colon carcinoma mouse model

Jenni H. Mäki-Jouppila, Tiina E. Kähkönen, Mari I. Suominen, Jussi M. Halleen, Jenni Bernoulli

Cancer Res (2019) 79 (13_Supplement): 4588.

DOI: https://doi.org/10.1158/1538-7445.AM2019-4588

Published: 01 July 2019

View article

Journal Articles

Abstract 2814: Systemic and local bone metastasis models for immuno-oncology drug development

Tiina E. Kähkönen, Mari I. Suominen, Jenni H. Mäki-Jouppila, Jussi M. Halleen, Arne Scholz, Jenni Bernoulli

Cancer Res (2019) 79 (13_Supplement): 2814.

DOI: https://doi.org/10.1158/1538-7445.AM2019-2814

Published: 01 July 2019

View article

Journal Articles

Abstract 3936: Efficacy of single agent radium-223 in the syngeneic MBT-2 bladder cancer bone growth model in mice

Tiina E. Kähkönen, Mari I. Suominen, Jenni H. Mäki-Jouppila, Birgitta Sjöholm, Ilmari Ahonen, Dominik Mumberg, Karl Ziegelbauer, Jussi M. Halleen, Sanna-Maria Käkönen, Arne Scholz

Cancer Res (2019) 79 (13_Supplement): 3936.

DOI: https://doi.org/10.1158/1538-7445.AM2019-3936

Published: 01 July 2019

View article

Journal Articles

Abstract 4614: Establishment of a HER2 positive breast cancer bone metastasis model for validation of novel therapies

Tiina E. Kähkönen, Mari I. Suominen, Jenni H. Mäki-Jouppila, Jussi M. Halleen, Jenni Bernoulli, Derek Grant

Cancer Res (2019) 79 (13_Supplement): 4614.

DOI: https://doi.org/10.1158/1538-7445.AM2019-4614

Published: 01 July 2019

View article

Journal Articles

Abstract 4850: The relevance of using proper preclinical models when developing therapeutics for localized or bone metastatic prostate cancer

Tiina E. Kähkönen, Jenni H.E. Mäki-Jouppila, Mari I. Suominen, Jussi M. Halleen, Jenni Bernoulli

Cancer Res (2019) 79 (13_Supplement): 4850.

DOI: https://doi.org/10.1158/1538-7445.AM2019-4850

Published: 01 July 2019

View article

Journal Articles

Abstract 1738: PD-1/PD-L1 expression and tumor-infiltrating immune cells in triple-negative breast cancer: Characterization of preclinical primary tumor and bone metastasis models in humanized mice

Tiina E. Kähkönen, Mari I. Suominen, Jussi M. Halleen, Azusa Tanaka, Michael Seiler, Teppo Haapaniemi, Jenni Bernoulli

Cancer Res (2018) 78 (13_Supplement): 1738.

DOI: https://doi.org/10.1158/1538-7445.AM2018-1738

Published: 01 July 2018

View article

Journal Articles

Abstract 1677: Differential efficacy of PD-1 targeted immunomodulation in preclinical models of primary and bone metastatic triple-negative breast cancer

Tiina E. Kähkönen, Mari I. Suominen, Jussi M. Halleen, Teppo Haapaniemi, Azusa Tanaka, Michael Seiler, Jenni Bernoulli

Cancer Res (2018) 78 (13_Supplement): 1677.

DOI: https://doi.org/10.1158/1538-7445.AM2018-1677

Published: 01 July 2018

View article

Journal Articles

Abstract 3859: Hormone receptor and HER2/HER3 expression in preclinical breast cancer models of primary tumor and bone metastasis

Tiina E. Kähkönen, Mari I. Suominen, Jussi M. Halleen, Jenni H. Mäki-Jouppila, Azusa Tanaka, Michael Seiler, Teppo Haapaniemi, Jenni Bernoulli

Cancer Res (2018) 78 (13_Supplement): 3859.

DOI: https://doi.org/10.1158/1538-7445.AM2018-3859

Published: 01 July 2018

View article

Journal Articles

Abstract 2684: Drug sensitivity profiling of BT-474 breast cancer cell line for identification of novel therapies targeting HER2-positive breast cancer

Jenni H. Mäki-Jouppila, Tiina E. Kähkönen, Mari I. Suominen, Jussi M. Halleen, Jenni Bernoulli, Jani Saarela, Katja Fagerlund

Cancer Res (2018) 78 (13_Supplement): 2684.

DOI: https://doi.org/10.1158/1538-7445.AM2018-2684

Published: 01 July 2018

View article

Journal Articles

Abstract 1162: Castration-resistant prostate cancer bone metastasis model to assess new therapeutics

Tiina E. Kähkönen, Mari I. Suominen, Jussi M. Halleen, Jenni Bernoulli, Pascale Lejeune

Cancer Res (2018) 78 (13_Supplement): 1162.

DOI: https://doi.org/10.1158/1538-7445.AM2018-1162

Published: 01 July 2018

View article

Journal Articles

Abstract 709: Anti-PD-1 therapy reduces bone lesion growth in a novel syngeneic bladder cancer bone metastasis model

Tiina E. Kähkönen, Mari I. Suominen, Jussi M. Halleen, Jenni Bernoulli, Arne Scholz

Cancer Res (2018) 78 (13_Supplement): 709.

DOI: https://doi.org/10.1158/1538-7445.AM2018-709

Published: 01 July 2018

View article

Journal Articles

Abstract 2823: Immunodeficient mice differentially sensitize to estrogen and exhibit severe estrogen-related adverse effects in orthotopic breast cancer model

Tiina E. Kähkönen, Mari I. Suominen, Jenni Mäki-Jouppila, Jussi Halleen, Azusa Tanaka, Michael P. Seiler, Jenni Bernoulli

Cancer Res (2017) 77 (13_Supplement): 2823.

DOI: https://doi.org/10.1158/1538-7445.AM2017-2823

Published: 01 July 2017

View article

Journal Articles

Abstract 1663: Preclinical efficacy model to promote immunotherapy development for prostate cancer

Mari I. Suominen, Tiina Kähkönen, Yvonne Konkol, Jenni Mäki-Jouppila, Jussi M. Halleen, Jenni Bernoulli

Cancer Res (2017) 77 (13_Supplement): 1663.

DOI: https://doi.org/10.1158/1538-7445.AM2017-1663

Published: 01 July 2017

View article

Journal Articles

Abstract 3838: Drug sensitivity profile of 5TGM1 murine multiple myeloma cell line emphasizes the translational potential of the syngeneic in vivo model

Jenni Mäki-Jouppila, Jenni Bernoulli, Mari I. Suominen, Tiina Kähkönen, Jussi M. Halleen, Sanna Timonen, Elina Huovari, Katja Suomi, Swapnil Potdar, Maria Nurmi, Päivi Östling, Jani Saarela, Katja M. Fagerlund

Cancer Res (2017) 77 (13_Supplement): 3838.

DOI: https://doi.org/10.1158/1538-7445.AM2017-3838

Published: 01 July 2017

View article

2 3

NARROW

Abstract 3318: PSMA-targeted thorium-227 conjugate (PSMA-TTC) inhibits tumor growth and abnormal bone changes in the intratibial LNCaP xenograft model of bone-metastatic prostate cancer

Abstract 1392: Synergistic antitumor efficacy of radium-223 in combination with enzalutamide in the intratibial LNCaP prostate cancer xenograft model

Abstract 1806: Novel preclinical orthotopic and bone metastasis TNBC models for assessment of immunotherapy and chemotherapy responses

Abstract 6286: The effects of prednisone, abiraterone acetate and radium-223 dichloride on bone in the intratibial LNCaP prostate cancer model

Abstract 5026: Efficacy of anti-PD-1, IDO inhibitor, chemotherapy and bone-targeting agent on tumor growth in a syngeneic bone metastasis model of triple-negative breast cancer

Abstract 2007: Validation of a preclinical model for bone metastatic triple negative breast cancer

Abstract 4588: Characterization of anti-CTLA-4 effects on tumor growth and immune microenvironment in a syngeneic CT26.WT colon carcinoma mouse model

Abstract 2814: Systemic and local bone metastasis models for immuno-oncology drug development

Abstract 3936: Efficacy of single agent radium-223 in the syngeneic MBT-2 bladder cancer bone growth model in mice

Abstract 4614: Establishment of a HER2 positive breast cancer bone metastasis model for validation of novel therapies

Abstract 4850: The relevance of using proper preclinical models when developing therapeutics for localized or bone metastatic prostate cancer

Abstract 1738: PD-1/PD-L1 expression and tumor-infiltrating immune cells in triple-negative breast cancer: Characterization of preclinical primary tumor and bone metastasis models in humanized mice

Abstract 1677: Differential efficacy of PD-1 targeted immunomodulation in preclinical models of primary and bone metastatic triple-negative breast cancer

Abstract 3859: Hormone receptor and HER2/HER3 expression in preclinical breast cancer models of primary tumor and bone metastasis

Abstract 2684: Drug sensitivity profiling of BT-474 breast cancer cell line for identification of novel therapies targeting HER2-positive breast cancer

Abstract 1162: Castration-resistant prostate cancer bone metastasis model to assess new therapeutics

Abstract 709: Anti-PD-1 therapy reduces bone lesion growth in a novel syngeneic bladder cancer bone metastasis model

Abstract 2823: Immunodeficient mice differentially sensitize to estrogen and exhibit severe estrogen-related adverse effects in orthotopic breast cancer model

Abstract 1663: Preclinical efficacy model to promote immunotherapy development for prostate cancer

Abstract 3838: Drug sensitivity profile of 5TGM1 murine multiple myeloma cell line emphasizes the translational potential of the syngeneic in vivo model

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only